Therapeutic procedures in pathologic endometrial hypertrophy
Niesłuchowska, B.; Witkowski, J.; Marianowski, L.; Czerkwiński, J.; Kozłowski, W.
Ginekologia Polska 51(8): 721-730
1980
ISSN/ISBN: 0017-0011 PMID: 6159254 Document Number: 160866
In 60 women demonstrating pathological endometrial hypertrophy, 42 were qualified for hormonal treatment (in 18 the diagnosis was hyperplasia glandularis; in 5, hyperplasia glandularis cystica; in 19, hyperplasia polyposa). A correlation was found between the hyperplasia and arterial hypertension, obesity, early menarche, number of passes deliveries and presence of uterine bleeding more than 1 yr after menopause. The cytohormonal vaginal smears revealed estrogenic hyperactivity. There were 2 groups with different therapeutic access. In group A, 24 women underwent sequential therapy (dienestrol 2.5 mg daily through 14 days, followed by chlormadinon 2.0 mg daily through 7 days). In group B, 18 women underwent continuous therapy (chlormadinon 6 mg daily through 6-8 wk). The following results were observed: in group A, 88.8% showed improvement and 11.2% treatment failures; in group B, 87.5 showed improvement and 12.5% treatment failure. Both methods can be viewed as equivalent in the treatment of pathological endometrial hyperplasia.